

# Lamivudine monotherapy in HIV-1-infected patients has been evaluated in a randomized pilot study (E-184V study)

Aids

20, 795-803

DOI: [10.1097/01.aids.0000218542.08845.b2](https://doi.org/10.1097/01.aids.0000218542.08845.b2)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Issues in the design of trials comparing management strategies for heavily pretreated patients. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 476-481.	1.5	1
2	Evaluation and management of early virological failure. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 409-416.	1.5	0
3	Management of the highly experienced patient. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 424-429.	1.5	0
4	Diminished Selection for Thymidine-Analog Mutations Associated With the Presence of M184V in Ethiopian Children Infected With HIV Subtype C Receiving Lamivudine-Containing Therapy. <i>Pediatric Infectious Disease Journal</i> , 2006, 25, 1049-1056.	1.1	25
5	Clinical trials for heavily pretreated patients: update in 2006. <i>Current Opinion in HIV and AIDS</i> , 2006, 1, 495-501.	1.5	2
6	British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). <i>HIV Medicine</i> , 2006, 7, 487-503.	1.0	193
7	Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 57, 1055-1064.	1.3	7
8	Lamivudine Monotherapy in an HIV-Infected Patient With the M184V Mutation. <i>Journal of the International Association of Providers of AIDS Care</i> , 2006, 5, 121-122.	1.2	0
9	Apricitabine: A Novel Deoxycytidine Analogue Nucleoside Reverse Transcriptase Inhibitor for the Treatment of Nucleoside-Resistant HIV Infection. <i>Antiviral Chemistry and Chemotherapy</i> , 2007, 18, 61-70.	0.3	16
10	Improved Interpretation of Genotypic Changes in the HIV Reverse Transcriptase Coding Region That Determine the Virological Response to Didanosine. <i>Journal of Infectious Diseases</i> , 2007, 196, 1645-1653.	1.9	16
11	Association of HIV-1 Replication Capacity With Treatment Outcomes in Patients With Virologic Treatment Failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 411-417.	0.9	13
12	Antiretroviral treatment of HIV infection: Swedish recommendations 2007. <i>Scandinavian Journal of Infectious Diseases</i> , 2007, 39, 486-507.	1.5	18
13	Human Immunodeficiency Virus Type 1: Resistance to Nucleoside Analogues and Replicative Capacity in Primary Human Macrophages. <i>Journal of Virology</i> , 2007, 81, 4540-4550.	1.5	25
14	Reply to Vogenthaler. <i>Clinical Infectious Diseases</i> , 2007, 44, 1387-1388.	2.9	1
15	Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 206-209.	1.3	8
16	Long-Term Immunologic and Virologic Responses in Patients with Highly Resistant HIV Infection Who Are Treated with an Incompletely Suppressive Antiretroviral Regimen. <i>Clinical Infectious Diseases</i> , 2007, 45, 1085-1092.	2.9	5
17	Treatment interruption in advanced failing patients. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 39-45.	1.5	5
18	Partial treatment interruptions. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 46-55.	1.5	3

#	ARTICLE	IF	CITATIONS
19	Risk of selecting resistance mutations during treatment interruption. <i>Current Opinion in HIV and AIDS</i> , 2007, 2, 6-13.	1.5	4
20	Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. <i>Aids</i> , 2007, 21, 1449-1455.	1.0	70
21	Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. <i>Aids</i> , 2007, 21, 721-732.	1.0	85
22	Approach to the Treatment-Experienced Patient. <i>Infectious Disease Clinics of North America</i> , 2007, 21, 85-102.	1.9	9
23	Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection. <i>Retrovirology</i> , 2007, 4, 25.	0.9	49
24	Is reduction of viral fitness a valid antiviral approach?. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2007, 4, 267-272.	0.5	0
25	Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. <i>HIV Medicine</i> , 2007, 8, 529-535.	1.0	16
26	Observational Study on HIV-Infected Subjects Failing HAART Receiving Tenofovir Plus Didanosine as NRTI Backbone. <i>Infection</i> , 2007, 35, 451-456.	2.3	3
27	HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. <i>Journal of Medical Virology</i> , 2008, 80, 201-208.	2.5	17
28	Perspectives and opportunities for novel antiviral treatments targeting virus fitness. <i>Clinical Microbiology and Infection</i> , 2008, 14, 629-631.	2.8	10
29	Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study. <i>HIV Medicine</i> , 2008, 9, 508-513.	1.0	8
30	Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. <i>Lancet, The</i> , 2008, 371, 1443-1451.	6.3	158
31	Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. <i>Aids</i> , 2008, 22, 1417-1423.	1.0	92
32	Transient Treatment Exclusively Containing Nucleoside Analogue Reverse Transcriptase Inhibitors in Highly Antiretroviral-Experienced Patients Preserves Viral Benefit When a Fully Active Therapy Was Initiated. <i>HIV Clinical Trials</i> , 2008, 9, 387-398.	2.0	7
33	Determination of Clinically Relevant Cutoffs for HIV-1 Phenotypic Resistance Estimates Through a Combined Analysis of Clinical Trial and Cohort Data. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 48, 26-34.	0.9	28
34	Managing Antiretroviral Therapy: Changing Regimens, Resistance Testing, and the Risks from Structured Treatment Interruptions. <i>Journal of Infectious Diseases</i> , 2008, 197, S261-S271.	1.9	24
35	Current Clinical Treatments of AIDS. <i>Advances in Pharmacology</i> , 2008, 56, 27-73.	1.2	8
36	Antiretroviral Therapy in HIV-Infected Patients with Multidrug-Resistant Virus: Applying the Guidelines to Practice. <i>AIDS Patient Care and STDs</i> , 2008, 22, 931-940.	1.1	6

#	ARTICLE	IF	CITATIONS
37	Recent Availability of Two Novel, Fixed Formulations of Antiretroviral Nucleoside Analogues: A 12-Month Prospective, Open-Label Survey of Their Practical Use and Therapeutic Perspectives in Antiretroviral-Naïve and -Experienced Patients. <i>AIDS Patient Care and STDs</i> , 2008, 22, 279-290.	1.1	5
38	Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching. <i>Aids</i> , 2008, 22, 2053-2067.	1.0	26
39	Antiviral drug development: progress and pitfalls. <i>Future Virology</i> , 2008, 3, 529-532.	0.9	0
40	The Place of protease inhibitors in antiretroviral treatment. <i>Brazilian Journal of Infectious Diseases</i> , 2009, 13, 371-374.	0.3	10
41	In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant Human Immunodeficiency Virus Type 1 in the Absence of Lamivudine. <i>Journal of Virology</i> , 2009, 83, 2038-2043.	1.5	76
42	Survival of HIV-1 Infected Multidrug-Resistant Patients Recycling Enfuvirtide After a Previous Failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 179-184.	0.9	4
43	Minority drug-resistant HIV-1 variants: transmission and response to antiretroviral therapy. <i>HIV Therapy</i> , 2009, 3, 55-61.	0.6	0
44	Treatment outcomes and plasma level of ritonavir-boosted lopinavir monotherapy among HIV-infected patients who had NRTI and NNRTI failure. <i>AIDS Research and Therapy</i> , 2009, 6, 30.	0.7	9
45	Multidrug resistance: a clinical approach. <i>Current Opinion in HIV and AIDS</i> , 2009, 4, 499-506.	1.5	3
46	The risk of HIV drug resistance following implementation of pre-exposure prophylaxis. <i>Current Opinion in Infectious Diseases</i> , 2010, 23, 621-627.	1.3	24
47	The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. <i>Aids</i> , 2010, 24, 1917-1922.	1.0	30
48	Antiretroviral Therapy in HIV-Infected Infants and Children. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 360-363.	1.1	4
49	Current and future management of treatment failure in low- and middle-income countries. <i>Current Opinion in HIV and AIDS</i> , 2010, 5, 83-89.	1.5	17
50	Estimated average annual rate of change of CD4+ T-cell counts in patients on combination antiretroviral therapy. <i>Antiviral Therapy</i> , 2010, 15, 563-570.	0.6	12
51	Monitoring Antiretroviral Therapy in Resource-Limited Settings: Balancing Clinical Care, Technology, and Human Resources. <i>Current HIV/AIDS Reports</i> , 2010, 7, 168-174.	1.1	15
52	Clinical management of HIV-1 resistance. <i>Antiviral Research</i> , 2010, 85, 245-265.	1.9	77
53	Second-line treatment in the Malawi antiretroviral programme: high early mortality, but good outcomes in survivors, despite extensive drug resistance at baseline. <i>HIV Medicine</i> , 2010, 11, 510-518.	1.0	82
54	Human immunodeficiency virus type 1 fitness and tropism: concept, quantification, and clinical relevance. <i>Clinical Microbiology and Infection</i> , 2010, 16, 1532-1538.	2.8	18

#	ARTICLE	IF	CITATIONS
55	Prior Therapy Influences the Efficacy of Lamivudine Monotherapy in Patients with Lamivudine-resistant HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 54, 51-58.	0.9	9
56	International Cohort Analysis of the Antiviral Activities of Zidovudine and Tenofovir in the Presence of the K65R Mutation in Reverse Transcriptase. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1520-1525.	1.4	9
57	Comparison of Antiviral Activity of Regimens Containing Nucleos(t)ide (NUC) Pairs in HIV-Infected Patients Initiating REScue Therapy (The NUCREST Study). <i>HIV Clinical Trials</i> , 2010, 11, 294-302.	2.0	1
58	Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. <i>The Cochrane Library</i> , 2010, , CD006517.	1.5	14
59	Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: A pilot randomised trial. <i>Journal of Clinical Virology</i> , 2010, 47, 253-257.	1.6	4
61	Antiretroviral therapy and management of HIV infection. <i>Lancet, The</i> , 2010, 376, 49-62.	6.3	348
62	Lamivudine for the treatment of HIV. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 105-114.	1.5	28
63	Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost?. <i>Clinical Infectious Diseases</i> , 2011, 53, 1265-1270.	2.9	94
64	Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committee. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2011, 22, 52-60.	0.7	6
65	Transmitted Drug Resistance in the CFAR Network of Integrated Clinical Systems Cohort: Prevalence and Effects on Pre-Therapy CD4 and Viral Load. <i>PLoS ONE</i> , 2011, 6, e21189.	1.1	28
66	Prior Therapy Influences the Efficacy of Lamivudine Monotherapy in Patients With Lamivudine-Resistant HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2011, 56, e34-e35.	0.9	1
67	Lower CD4 Cell Count and Higher Virus Load, but Not Antiretroviral Drug Resistance, Are Associated with AIDS-Defining Events and Mortality: An ACTG Longitudinal Linked Randomized Trials (ALLRT) Analysis. <i>HIV Clinical Trials</i> , 2011, 12, 79-88.	2.0	8
68	Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. <i>Clinical Microbiology and Infection</i> , 2011, 17, 928-934.	2.8	20
69	High efficacy of lopinavir/râ€based secondâ€line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. <i>Journal of the International AIDS Society</i> , 2011, 14, 14-14.	1.2	33
70	It is time to consider thirdâ€line options in antiretroviralâ€experienced paediatric patients?. <i>Journal of the International AIDS Society</i> , 2011, 14, 55-55.	1.2	15
71	Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption. <i>Infection</i> , 2011, 39, 121-126.	2.3	12
72	<i>No pol</i> mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2011, 83, 391-398.	2.5	1
73	Single-Boosted Protease Inhibitor versus Double-Boosted Protease Inhibitors for the Salvage Therapy in HIV-Infected Patients. <i>Journal of the International Association of Providers of AIDS Care</i> , 2011, 10, 105-110.	1.2	0

#	ARTICLE	IF	CITATIONS
74	Residual Activity of Two HIV Antiretroviral Regimens Prescribed without Virological Monitoring. Antimicrobial Agents and Chemotherapy, 2011, 55, 4575-4580.	1.4	2
75	The Role of Inactive Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Salvage Therapy for Drug-Resistant HIV-1 Infection in the Era of New Classes and New Generation Antiretrovirals. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 58, e46-e48.	0.9	1
76	Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation Classes. Journal of Infectious Diseases, 2011, 203, 1174-1181.	1.9	125
77	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Medicine, 2012, 13, 1-6.	1.0	149
79	Tenofovir-based regimens associated with less drug resistance in HIV-1-infected Nigerians failing first-line antiretroviral therapy. Aids, 2013, 27, 553-561.	1.0	21
80	Preexposure prophylaxis will have a limited impact on HIV-1 drug resistance in sub-Saharan Africa. Aids, 2013, 27, 2943-2951.	1.0	61
81	Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescents. Journal of the International AIDS Society, 2013, 16, 18579.	1.2	159
82	Virological failure and drug resistance during first line antiretroviral treatment in Indonesia. Journal of Medical Virology, 2013, 85, 1394-1401.	2.5	14
83	Use of Nucleoside Reverse Transcriptase Inhibitor-only Regimens in HIV-infected Children and Adolescents. Pediatric Infectious Disease Journal, 2013, 32, e370-e376.	1.1	1
84	Managing virological failure. HIV Medicine, 2014, 15, 48-57.	1.0	2
85	Short Communication: Focal Encephalitis Related to Viral Escape and Resistance Emergence in Cerebrospinal Fluid in a Patient on Lopinavir/Ritonavir Monotherapy with Plasma HIV-1 RNA Suppression. AIDS Research and Human Retroviruses, 2014, 30, 984-987.	0.5	27
87	Removing inactive NRTIs in a salvage regimen is safe, maintains virological suppression and reduces treatment costs: results from the VERITAS study (TMC114HIV4054). HIV Clinical Trials, 2015, 16, 111-116.	2.0	9
88	Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race/ethnicity determine the degree of regimen complexity. HIV Clinical Trials, 2015, 16, 147-156.	2.0	12
90	Systems Approach to targeted and long-acting HIV/AIDS therapy. Drug Delivery and Translational Research, 2015, 5, 531-539.	3.0	16
91	Lamivudine Monotherapy. Pediatric Infectious Disease Journal, 2016, 35, e199-e205.	1.1	6
92	Drug resistance mutations after the first 12 months on antiretroviral therapy and determinants of virological failure in Rwanda. Tropical Medicine and International Health, 2016, 21, 928-935.	1.0	39
93	HIV-1 drug resistance and resistance testing. Infection, Genetics and Evolution, 2016, 46, 292-307.	1.0	215
94	British HIV Association guidelines for the treatment of HIV-positive adults with antiretroviral therapy 2015. HIV Medicine, 2016, 17, s2-s104.	1.0	78

#	ARTICLE	IF	CITATIONS
95	Withdrawing inactive NRTIs in HIV-1 subjects with suppressed viraemia: a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1346-1351.	1.3	3
96	Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12) Tj ETQq1,1 0.784314 rgBT e384-e392.	2.1	63
97	The interaction between equipoise and logistics in clinical trials: A case study. <i>Clinical Trials</i> , 2017, 14, 314-318.	0.7	6
98	Resistance matters in EARNEST. <i>Lancet HIV,the</i> , 2017, 4, e323-e324.	2.1	6
99	The Association between Detected drug Resistance Mutations and CD4<sup>+</sup>T-Cell Decline in HIV-Positive Individuals Maintained on a Failing Treatment Regimen. <i>Antiviral Therapy</i> , 2018, 23, 105-116.	0.6	3
100	Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 125-135.	0.9	59
101	Rethinking recycling nucleoside reverse transcriptase inhibitors in HIV treatment. <i>Aids</i> , 2018, 32, 835-840.	1.0	1
102	geno2pheno[ngs-freq]: a genotypic interpretation system for identifying viral drug resistance using next-generation sequencing data. <i>Nucleic Acids Research</i> , 2018, 46, W271-W277.	6.5	37
103	A Therapeutic Perspective of Living with Human Immunodeficiency Virus/AIDS inÂ2017. <i>Nursing Clinics of North America</i> , 2018, 53, 97-110.	0.7	5
104	Lamivudine monotherapy as a holding regimen for HIV-positive children. <i>PLoS ONE</i> , 2018, 13, e0205455.	1.1	4
105	Dual antiretroviral therapy with tenofovir (TDF) and darunavir/ritonavir (DRV/RTV) in an HIV-1 positive patient: a case report, review, and meta-analysis of the literature on dual treatment strategies using protease inhibitors in combination with an NRTI. <i>Infection</i> , 2018, 46, 599-605.	2.3	2
106	Use and Outcomes of Antiretroviral Monotherapy and Treatment Interruption in Adolescents With Perinatal HIV Infection in Asia. <i>Journal of Adolescent Health</i> , 2019, 65, 651-659.	1.2	0
107	What Should We Do When HIV-positive Children Fail First-line Combination Antiretroviral Therapy? A Comparison of 4 ART Management Strategies. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 400-405.	1.1	4
108	Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 35-42.	1.1	19
109	Clinical trials of antiretroviral treatment interruption in HIV-infected individuals. <i>Aids</i> , 2019, 33, 773-791.	1.0	34
110	Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study. <i>Lancet HIV,the</i> , 2019, 6, e116-e127.	2.1	84
111	Virologic suppression in patients with a documented M184V/I mutation based on the number of active agents in the antiretroviral regimen. <i>SAGE Open Medicine</i> , 2020, 8, 205031212096057.	0.7	1
112	Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO). <i>EBioMedicine</i> , 2020, 55, 102779.	2.7	28

#	ARTICLE	IF	CITATIONS
113	Impact of archived M184V/I mutation on the effectiveness of switch to co-formulated elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide among virally suppressed people living with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2986-2993.	1.3	6
114	Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation. <i>HIV Medicine</i> , 2020, 21, 309-321.	1.0	3
115	Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients. <i>International Journal of Antimicrobial Agents</i> , 2020, 55, 105893.	1.1	28
116	Pretreatment HIV drug resistance predicts accumulation of new mutations in ART-naïve Ugandan children. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2020, 109, 2706-2716.	0.7	5
117	New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 98-103.	0.9	1
118	Antiretroviral Drug Treatment of Individuals that Used Preexposure Prophylaxis (PrEP) Before Diagnosis. <i>Current Treatment Options in Infectious Diseases</i> , 2021, 13, 141-152.	0.8	0
119	The clinical challenges of lifetime HAART. , 2008, , 421-462.		2
120	In Vitro HIV-1 Evolution in Response to Triple Reverse Transcriptase Inhibitors & In Silico Phenotypic Analysis. <i>PLoS ONE</i> , 2013, 8, e61102.	1.1	12
121	Decline in CD4 T lymphocytes with monotherapy bridging strategy for non-adherent adolescents living with HIV infection: Results of the IMPAACT P1094 randomized trial. <i>PLoS ONE</i> , 2017, 12, e0178075.	1.1	1
122	Country review: Germany. , 2008, , 119-136.		0
123	Evaluation of HIV-1 viral load and genotypic resistance assays for resource-limited settings. <i>Afrika Focus</i> , 2008, 21, .	0.1	0
124	Clinical Implications of Reverse Transcriptase Inhibitor Resistance. , 2009, , 589-619.		0
125	HIV/AIDS and Opportunistic Illnesses. , 2009, , 373-401.		1
126	Changing antiretroviral therapy in children. <i>Southern African Journal of HIV Medicine</i> , 2009, 10, 85.	0.3	0
127	Antiretroviral therapy for HIV. , 2010, , 556-566.		1
128	In Vivo Validation of a Bioinformatics Based Tool to Identify Reduced Replication Capacity in HIV-1. <i>Open Medical Informatics Journal</i> , 2010, 4, 225-232.	1.0	0
129	Simplification of Antiretroviral Therapy (ART). , 0, , .		0
130	Treatment Failure and Resistance. , 2015, , 1-7.		0



#	ARTICLE	IF	CITATIONS
131	Treatment Failure and Resistance. , 2018, , 2047-2053.		0
132	Fitness Cost of Antiretroviral Drug Resistance Mutations on the pol Gene during Analytical Antiretroviral Treatment Interruption among Individuals Experiencing Virological Failure. Pathogens, 2021, 10, 1425.	1.2	3
133	The renaissance of fixed dose combinations: Combivir. Therapeutics and Clinical Risk Management, 2007, 3, 579-83.	0.9	11
135	Lamivudine and Indinavir/Ritonavir Maintenance Therapy in Highly Pretreated HIV-Infected Patients (Vista Anrs 109). Antiviral Therapy, 2006, 11, 889-900.	0.6	4
136	Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients. Antiviral Therapy, 2009, 14, 339-347.	0.6	26
137	A Randomized Trial to Evaluate Continuation versus Discontinuation of Lamivudine in Individuals Failing A Lamivudine-Containing Regimen: The Colate Trial. Antiviral Therapy, 2006, 11, 761-770.	0.6	31